Stock listing

HKEX:6996 Antengene Corporation Limited (德琪醫藥) 股價

Home listing (HKEX) of Antengene Corporation Limited

Follow Antengene Corporation Limited into a list and get an email when it puts out news.

Share price · HKEX:6996

$2.35 HKD -0.17 (-6.7%)

Close on Nov 20, 2026

Past year -50.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.29 – $2.62 HKDNov 20, 2026
Volume
1.23M sharesNov 20, 2026
Market cap
$1.43B HKDAt the close on Nov 20, 2026 · price × 610.6M shares outstanding
52-week range
$2.29 – $6.28 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.21M HKDMedian day 870,550 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Antengene Corporation Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
HKEX:6996 · Home$2.35 HKD-0.17 (-6.7%)1,232,000$2.62$2.62$2.29$2.52Close on Nov 20, 2026
Frankfurt:722€0.248 EUR-0.022 (-8.1%)—€0.248€0.248€0.248€0.270Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:6996 · HKD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.35-0.17-6.7%$2.62$2.62$2.291,232,000
$2.52-0.01-0.4%$2.615$2.615$2.372,963,500
$2.53-0.065-2.5%$2.585$2.585$2.465654,500
$2.595-0.115-4.2%$2.90$2.90$2.525980,500
$2.71-0.11-3.9%$2.95$2.95$2.645503,500
$2.820.000.0%$2.955$2.955$2.76626,000
$2.820.000.0%$2.945$2.945$2.70374,500
$2.82+0.125+4.6%$2.905$2.905$2.76391,500
$2.695-0.125-4.4%$2.80$2.88$2.68382,000
$2.82-0.13-4.4%$2.89$2.89$2.725332,000
$2.95+0.14+5.0%$2.95$2.985$2.90566,500
$2.81+0.14+5.2%$2.67$2.85$2.6551,249,751
$2.67-0.16-5.7%$2.79$2.795$2.621,050,000
$2.83+0.04+1.4%$2.95$2.95$2.775221,000
$2.79-0.035-1.2%$2.99$2.99$2.775392,000
$2.825-0.015-0.5%$2.90$2.90$2.735282,000
$2.84+0.065+2.3%$2.705$2.89$2.7051,049,500
$2.775-0.165-5.6%$3.025$3.025$2.7351,096,500
$2.94+0.055+1.9%$2.98$2.98$2.84338,000
$2.885+0.045+1.6%$3.00$3.00$2.73829,000
$2.84-0.175-5.8%$3.09$3.09$2.8151,823,191
$3.015-0.05-1.6%$3.08$3.10$2.971,426,500
$3.065-0.015-0.5%$3.08$3.115$2.95948,000
$3.08+0.11+3.7%$3.10$3.165$3.00704,500
$2.970.000.0%$3.00$3.12$2.905730,000
$2.97+0.035+1.2%$3.06$3.06$2.90858,100
$2.935-0.12-3.9%$3.13$3.13$2.88805,500
$3.055-0.135-4.2%$3.225$3.225$3.045883,000
$3.19-0.12-3.6%$3.35$3.35$3.0651,539,500
$3.31-0.19-5.4%$3.50$3.50$3.27980,500
$3.50-0.03-0.8%$3.53$3.53$3.365392,500
$3.53+0.14+4.1%$3.40$3.54$3.365378,000
$3.39+0.065+2.0%$3.50$3.50$3.25425,500
$3.325-0.135-3.9%$3.405$3.405$3.20742,500
$3.46+0.06+1.8%$3.40$3.535$3.40632,500
$3.40+0.04+1.2%$3.56$3.56$3.32578,000
$3.36-0.11-3.2%$3.555$3.555$3.34741,500
$3.47-0.005-0.1%$3.475$3.575$3.34505,500
$3.475-0.105-2.9%$3.58$3.58$3.40944,500
$3.58+0.04+1.1%$3.66$3.66$3.5551,442,000
$3.54-0.045-1.3%$3.585$3.665$3.501,161,500
$3.585+0.275+8.3%$3.31$3.645$3.301,231,000
$3.31+0.06+1.8%$3.50$3.50$3.295948,000
$3.25-0.03-0.9%$3.28$3.345$3.1851,729,500
$3.28-0.07-2.1%$3.575$3.575$3.26764,500
$3.35-0.075-2.2%$3.27$3.57$3.265530,500
$3.425+0.085+2.5%$3.20$3.48$3.20698,500
$3.34-0.11-3.2%$3.50$3.50$3.161,492,500
$3.450.000.0%$3.53$3.53$3.33722,000
$3.45-0.05-1.4%$3.555$3.555$3.42510,000
$3.500.000.0%$3.66$3.66$3.39551,150
$3.50-0.055-1.5%$3.695$3.695$3.4151,420,500
$3.555-0.025-0.7%$3.77$3.77$3.5251,051,500
$3.58+0.02+0.6%$3.77$3.77$3.545679,000
$3.56+0.01+0.3%$3.81$3.81$3.451,007,500
$3.55-0.125-3.4%$3.83$3.83$3.5251,072,500
$3.675-0.185-4.8%$3.99$3.99$3.612,203,500
$3.86-0.185-4.6%$4.00$4.03$3.8051,763,000
$4.045+0.01+0.2%$4.095$4.195$3.981,175,000
$4.035+0.055+1.4%$4.075$4.19$3.991,435,000
$3.98+0.09+2.3%$4.05$4.12$3.901,959,500
$3.89-0.015-0.4%$4.075$4.185$3.851,340,000
$3.905-0.115-2.9%$3.935$4.02$3.751,776,166
$4.02+0.27+7.2%$3.87$4.125$3.842,090,893
Ticker
HKEX:6996
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
HKEX
Currency
HKD

What changed lately

Latest news

All Antengene Corporation Limited news

Antengene Corporation Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
62 in the last 12 months · 76 in all · newest Nov 20, 2026 · oldest 2025
Decks
2 decks · latest November 2022

Where Antengene Corporation Limited is listed

ListingExchangeCountryCurrency
HKEX:6996 德琪醫藥 · Home listing · This pageHKEXHong KongHKD
Frankfurt:722FrankfurtGermanyEUR
LS Exchange:A2QHCZLS ExchangeGermanyEUR
Lang & Schwarz:A2QHCZLang & SchwarzGermanyEUR
Stuttgart:722StuttgartGermanyEUR
Tradegate:722TradegateGermanyEUR

Valuation

EV/sales 6.8× against a median of 59.4×: the lowest of 7 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$838.4M HKD
P/E
Loss
EV/sales
6.8×
EV/EBITDA
Negative EBITDA
Price/book
1.3×
Gross margin
82.4%
Operating margin
−226.8%
Net margin
−227.0%
Debt to equity
0.3×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Antengene Corporation Limited · HKEX:6996US$183.1MUS$107.0Mn/a6.8×n/a1.3×−227.0%0.3×n/a
Cartesian Therapeutics, Inc. · NASDAQ:RNACUS$187.3MUS$114.5Mn/a112×n/an/an/an/a1.23
Artiva Biotherapeutics, Inc. · NASDAQ:ARTVUS$186.9M−US$123.1Mn/an/an/a0.6×n/a0.0×1.34
Inhibikase Therapeutics, Inc. · NASDAQ:IKTUS$185.2M−US$8.17Mn/an/an/a1.0×n/a0.0×1.50
Inventage Lab, Inc. · KRX:389470US$184.8MUS$112.6Mn/a61.3×n/a2.8×−127.0%0.2×n/a
Whitehawk Therapeutics, Inc. · NASDAQ:WHWKUS$181.2MUS$11.70Mn/an/an/a1.1×n/a0.0×1.35
Sol-Gel Technologies Ltd. · NASDAQ:SLGLUS$180.6MUS$137.0Mn/a95.4×n/a4.2×n/a0.0×0.67
Tanvex BioPharma, Inc. · TWSE:6541US$180.5MUS$225.7Mn/a11.3×n/a1.2×−222.8%0.4×n/a
Korro Bio, Inc. · NASDAQ:KRROUS$179.4MUS$74.36Mn/a57.6×n/a2.0×n/a0.0×1.46
Vogenx Inc · NASDAQ:VOGXUS$176.3MUS$94.21Mn/an/an/a2.1×n/a0.0×n/a
MediWound Ltd. · NASDAQ:MDWDUS$175.5MUS$155.9Mn/a15.6×n/a5.5×−235.0%0.3×0.64
Median of the othersUS$180.9MUS$103.4M59.4×2.0×−222.8%0.0×1.34

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
4.88 HKD · Analysts' mean
EPS, year to Dec 2026
0.53 · 1 analyst
Revenue, year to Dec 2026
830.3M · 1 analyst

Team and board

Officers

OfficerRole
Jay MeiExecutive Director, Chairman of the Board, Chief Executive Officer
Peter QianPR / IR Contacts
Bing HouExecutive Director

Board

DirectorRole
Jay MeiExecutive Director, Chairman of the Board, Chief Executive Officer
Bing HouExecutive Director
Jing QianIndependent non-executive Director
Rafael FonsecaIndependent non-executive Director
Robert GaleIndependent non-executive Director
Sheng TangIndependent non-executive Director

Events

QuarterResultsShare move
Q2 2025Aug 21, 2025 · Before open+1.3%
Quarter to Mar 31, 2025Jun 13, 2025 · Before open−9.3%
Q4 2024Mar 21, 2025+11.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2022)Investor deck42 slidesNovember 2022
Investor Presentation (November 2021)Investor deck32 slidesNov 29, 2021

Open Decks

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue105.3M92.0M67.3M160.1M28.8M011.0M6.80M
Cost of revenue18.5M17.8M12.3M28.1M4.58M0
Gross profit86.8M74.2M55.0M132.0M24.2M011.0M6.80M
Research and development169.1M258.9M405.7M488.5M405.0M347.7M115.8M115.8M
Selling, general and administrative87.5M106.3M148.1M167.1M169.5M154.2M39.3M12.8M
Operating income-238.9M-364.7M-691.5M-878.9M-618.2M-502.3M-144.1M-134.8M
Depreciation and amortization23.9M26.9M30.0M27.2M11.5M4.09M1.51M763.0K
EBITDA-215.0M-337.8M-661.5M-851.7M-606.7M-498.2M-142.6M-134.0M
Interest expense2.30M642.0K898.0K974.0K698.0K1.03M836.0K11.2M
Income before tax-239.1M-319.3M-581.2M-601.5M-655.5M-2.93B-323.8M-146.0M
Income tax12.6M3.69M
Net income-239.1M-319.3M-581.2M-601.5M-655.5M-2.93B-323.8M-146.0M
Earnings per share, basic-0.38-0.51-0.94-0.97-1.05-11.66-0.48-0.22

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents734.2M900.1M1.19B1.79B2.27B3.11B290.8M49.3M
Short-term investments107.0K106.0K4.90M3.43M2.33M1.70M453.4M
Receivables27.5M18.7M9.68M29.8M7.01M17.5M8.35M11.4M
Inventory7.53M13.2M15.3M9.89M2.58M0
Current assets783.5M956.2M1.24B1.90B2.41B3.13B755.6M77.1M
Property, plant and equipment57.7M229.4M86.1M66.1M4.09M3.28M
Total assets1.26B1.34B1.62B2.14B2.56B3.19B759.8M80.4M
Accounts payable7.99M3.58M3.86M7.82M1.48M16.5M
Current liabilities264.1M146.3M190.9M381.8M159.4M150.6M44.9M68.7M
Long-term debt191.0M220.0M180.0M30.0M001.27B138.1M
Total debt257.5M249.4M201.0M58.0M14.8M10.9M1.73B154.0M
Total liabilities614.9M493.9M471.2M428.8M163.3M156.6M1.32B239.0M
Shareholders' equity642.7M850.8M1.15B1.71B2.39B3.04B-557.6M-158.6M
Shares outstanding626.4M620.4M615.4M617.8M625.0M251.1M668.2M668.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-127.5M-322.0M-665.8M-572.2M-557.6M-307.1M-121.5M-113.1M
Capital spending-51.4M-60.6M-113.1M-93.4M-23.4M-51.7M-11.0K-450.0K
Free cash flow-178.9M-382.6M-778.9M-665.6M-581.0M-358.9M-121.5M-113.6M
Cash from investing116.2M345.2M587.1M-208.2M-103.9M-600.6M-430.4M96.8M
Cash from financing-3.19M45.2M131.8M-20.7M-81.3M2.79B771.8M31.6M
Share buybacks-1.39M00-33.8M-47.9M-139.6M806.0M0
Change in cash-15.4M69.7M56.6M-708.4M-780.1M1.80B241.5M19.0M

Open Financials

Filings

FilingDateTypeFiled with
Next Day Disclosure ReturnNov 20, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 19, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 18, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 17, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 16, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 13, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 12, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 11, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 10, 2026Next day disclosure returnHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026Nov 4, 2026Monthly returnHKEX
All 37 filings
FilingDateTypeFiled with
Next Day Disclosure ReturnNov 3, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 2, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 30, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 29, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 28, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 27, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 26, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 23, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 22, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 21, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 20, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 16, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 15, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 14, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 13, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 12, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 9, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 8, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 7, 2026Next day disclosure returnHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 7, 2026Monthly returnHKEX
Next Day Disclosure ReturnOct 6, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 5, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnOct 2, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnSep 30, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnSep 29, 2026Next day disclosure returnHKEX
2026 INTERIM REPORTSep 29, 2026Interim reportHKEX
Next Day Disclosure ReturnSep 28, 2026Next day disclosure returnHKEX

Open Filings

Cap table

Built by 6ix from Antengene Corporation Limited’s releases

Common shares
610,632,300
Fully diluted
610,632,300

Fully diluted

LineShares
Common shares610,632,300

Share count over time

CountShares
Nov 22, 2026610,632,300

Open Cap table

Shareholders

Register

HolderSharesOf the companyAs of
Mei Jay185M27.3%Sep 10, 2026
Meiland Pharma Tech SPC176M26.2%Sep 9, 2021
Jay Mei 2025 Grat176M25.9%Apr 27, 2026
The Core Trust Company Limited74.8M10.8%Sep 14, 2026
TCT (BVI) Limited74.8M10.8%Sep 14, 2026
FountainVest China Capital Partners GP3 Ltd.46.3M6.9%Nov 25, 2022
FountainVest China Capital Partners Fund III, L.P.46.3M6.9%Nov 25, 2022
Begonia Investment Ltd.46.3M6.9%Nov 25, 2022

Funds

HolderSharesValueAs of
State Street(R) SPDR(R) Portfolio Emerging Markets ETF1.31MUS$591KJun 30, 2026
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF291KUS$131KJun 30, 2026
State Street(R) SPDR(R) S&P(R) China ETF60,000US$27,008Jun 30, 2026
The Emerging Markets Small Cap Series49,000US$24,615Jul 31, 2026
World ex U.S. Core Equity Portfolio7,000US$3,516Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Qian Jing
Director or chief executive
Sale251HKD 2.63HKD 660Nov 4, 2026
Hou Bing
Director or chief executive
Sale3,472HKD 2.73HKD 9,465Nov 4, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bing HouExecutive Director · Since May 20, 2026
Jay MeiExecutive Director, Chairman of the Board, Chief Executive Officer · Since at least Aug 24, 2026
Jing QianIndependent non-executive Director · Since at least Nov 5, 2026
Peter QianPR / IR Contacts · Since at least Oct 3, 2026
Rafael FonsecaIndependent non-executive Director · Since at least Nov 5, 2026
Robert GaleIndependent non-executive Director · Since at least Nov 5, 2026
Sheng TangIndependent non-executive Director · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Antengene Corporation Limited.